Showing results (1-10 of 197) with videos related to
Sort By:
Pageof 20
Acta Oncologica (Stockholm, Sweden)|May 25, 2011
Broadening horizons in medical management of prostate cancerSaroj Niraula, Ian F TannockJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trialsSaroj Niraula, Lisa W Le, Ian F TannockEuropean Journal of Cancer (Oxford, England : 1990)|June 1, 2026
Conflicts of interest and interpretive authority in oncologySaroj Niraula, Samuel X Stevens, Tito Fojo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysisSaroj Niraula, Eitan Amir, Francisco Vera-Badillo, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 15, 2013
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 studySaroj Niraula, Greg Pond, Ronald de Wit, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugsSaroj Niraula, Bostjan Seruga, Alberto Ocana, et al.Future Science OA|December 20, 2017
Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancerSaroj Niraula, Arnoud J Templeton, Francisco Vera-Badillo, et al.Breast (Edinburgh, Scotland)|December 5, 2018
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their valueSaroj NiraulaPageof 20